This analysis demonstrates value and innovation of direct-acting antivirals for the treatment of chronic hepatitis C in the US Kaiser Permanente health system. Objectives: Direct-acting antivirals ...

Atea showcased its Phase III HCV programme at JPM for bemnifosbuvir/ruzasvir, positioning the regimen for test-and-treat ...

Please provide your email address to receive an email when new articles are posted on . Research shows donor kidneys with the hepatitis C virus have a 3-year graft survival. Selection was done ...

Hepatitis C infection. Computer illustration showing liver and close-up view of hepatitis C viruses. Studies show that mortality, morbidity, and hepatic decompensation risks increase with coinfection ...

Given that HCV is a bloodborne virus, any circumstance that promotes continued drug injection—including failure to prevent or diagnose and adequately treat substance use disorders—can result in ...

Most people infected by the hepatitis C virus (HCV) can be cured with antiviral therapy, but access to the treatment remains limited. Even diagnosis of hepatitis C, a disease that causes chronic ...

Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...

Between 1995 and 2023, diagnoses of hepatitis C infection increased among HIV-positive men who have sex with men with no history of injection drug use, particularly during the era of highly active ...

Pelosi is a scientific manager and researcher. Perkins is a senior advisor in governance. Remak is a patient advocate. Seid is a vaccine program lead. Romanowska is a fact-checking expert addressing ...

The fight against viral hepatitis has witnessed both remarkable triumphs and persistent challenges. As a doctor and researcher, I have witnessed firsthand how groundbreaking advancements in treatment ...